Improved dihydroergotamine (DHE) pharmacology following orally-inhaled delivery

被引：0

作者：

Cook, R. O. ^{[1
]}

Shrewsbury, S. B. ^{[1
]}

机构：

[1] MAP Pharmaceut Inc, Res & Dev, Mountain View, CA USA

来源：

HEADACHE | 2008年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S62 / S63

页数：2

共 50 条

[31] Comparable Efficacy and Safety Among Patients with and Without Aura: Orally Inhaled Dihydroergotamine (MAP0004) for the Acute Treatment of Migraine
Winner, P.
Holdbrook, F.
Davar, G.
HEADACHE, 2014, 54 : 14 - 15
[32] Improved delivery of inhaled steroids to the large and small airways
Leach, CL
RESPIRATORY MEDICINE, 1998, 92 : 3 - 8
[33] Significant tobramycin absorption following inhaled delivery.
Shaw, PK
Braun, TL
Liebergen, A
Conyers, K
Leff, RD
PEDIATRIC RESEARCH, 1996, 39 (04) : 2327 - 2327
[34] A Randomized, Double-Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of LEVADEX™ (MAP0004, Orally Inhaled DHE) and Intravenous DHE on Pulmonary Arterial Systolic Pressure
Berenberg, Ekatherina
Clemons, Desiree
Kellerman, Donald
Kori, Shashidhar
Noveck, Robert
NEUROLOGY, 2011, 76 (09) : A198 - A198
[35] Assessment of the consistency of pharmacokinetic parameters of levadex™ (map0004, orally inhaled dihydroergotamine) in healthy volunteers - results from 3 clinical studies
Forst, A.
Iwashita, J.
Kellerman, D.
Kori, S.
Thomas, T.
Taylor, G.
CEPHALALGIA, 2011, 31 (01) : 82 - 82
[36] Assessing the Consistency of LEVADEX™ (MAP0004, Orally Inhaled Dihydroergotamine) Pharmacokinetic Parameters in Healthy Volunteers: Results from 3 Clinical Studies
Forst, Amy
Iwashita, Julie
Kellerman, Don
Kori, Shashidhar
Thomas, Tracy
Taylor, Glyn
ANNALS OF NEUROLOGY, 2011, 70 : S64 - S64
[37] Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans
Kellerman, D.
Kori, S.
Forst, A.
Chang, J.
Febbraro, S.
WuTann, L.
Thomas, T.
Taylor, G.
Dodick, D. W.
CEPHALALGIA, 2012, 32 (02) : 150 - 158
[38] Assessment of the Consistency of Pharmacokinetic Parameters of LEVADEX™ (MAP0004, Orally Inhaled Dihydroergotamine) in Healthy Volunteers - Results from 3 Clinical Studies
Forst, A.
Iwashita, J.
Kellerman, D.
Kori, S.
Thomas, T.
Taylor, G.
HEADACHE, 2011, 51 : 22 - 22
[39] ASSESSING THE CONSISTENCY OF LEVADEX™ (MAP0004, ORALLY INHALED DIHYDROERGOTAMINE) PHARMACOKINETIC PARAMETERS IN HEALTHY VOLUNTEERS: RESULTS FROM 3 CLINICAL STUDIES
Frost, A.
Kellerman, D.
Kori, S.
Thomas, T.
Taylor, G.
EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 197 - 197
[40] MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments (vol 86, pg 948, 2011)
Tepper, Stewart J.
MAYO CLINIC PROCEEDINGS, 2011, 86 (12) : 1248 - 1248

← 1 2 3 4 5 →